Holen Sie sich die Stockscreener-App
7.46
7.65%
0.53
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
(CVKD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock - Defense World
Cadrenal Therapeutics Earnings Notes - Trefis
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - The Globe and Mail
How a small biotech is building an emergency anticoagulation plan - Stock Titan
Cadrenal Therapeutics announces new securities purchase agreement - MSN
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - ACCESS Newswire
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - The Globe and Mail
Cadrenal Therapeutics Appoints Dr. Golden to Board - MSN
Cadrenal Therapeutics Files Prospectus Supplement for ATM Offering - TradingView — Track All Markets
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis - Defense World
Downgrade Watch: Will Cadrenal Therapeutics Inc stock benefit from commodity pricesEarnings Beat & Detailed Earnings Play Alerts - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru
How Cadrenal Therapeutics Inc. stock performs in stagflation2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Cadrenal Therapeutics Inc. stock recession proofWeekly Profit Recap & Capital Efficient Trading Techniques - Улправда
Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Buying & Community Verified Trade Signals - Улправда
Can Cadrenal Therapeutics Inc. stock resist market sell offsJuly 2025 Movers & Technical Buy Zone Confirmations - Улправда
Can Cadrenal Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Summary & Daily Entry Point Trade Alerts - Улправда
What sentiment indicators say about Cadrenal Therapeutics Inc. stock2025 Trading Recap & Fast Momentum Stock Entry Tips - DonanımHaber
Aug PreEarnings: Is Cadrenal Therapeutics Inc. stock a contrarian buy2025 Market Sentiment & Weekly High Momentum Picks - DonanımHaber
Ideas Watch: Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Selling & Weekly Setup with ROI Potential - Улправда
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - Улправда
How Cadrenal Therapeutics Inc. stock responds to policy changes2025 Bull vs Bear & Expert Curated Trade Setups - Улправда
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Volume & Technical Pattern Based Signals - Улправда
Cadrenal Therapeutics to conduct partnering and investor meetings - marketscreener.com
Cadrenal Therapeutics To Conduct Partnering And Investor Meetings - TradingView — Track All Markets
Cadrenal Therapeutics, Inc. Management to Hold Investor and Partner Meetings at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - Sahm
Cadrenal Therapeutics to Conduct Partnering and Investor - GlobeNewswire
Cadrenal Therapeutics Announces New Securities Purchase Agreement - TipRanks
Understanding the Setup: (CVKD) and Scalable Risk - Stock Traders Daily
CVKDCadrenal Therape Latest Stock News & Market Updates - Stock Titan
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - guardonline.com
Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - Voice of Alexandria
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox By Investing.com - Investing.com Australia
Cadrenal Therapeutics acquires late-stage drug assets from Maryland biotech - The Business Journals
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox - Investing.com
Cadrenal Therapeutics Acquires VLX-1005 from Veralox - TipRanks
Cadrenal Therapeutics acquires VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for patients with heparin-induced thrombocytopenia - marketscreener.com
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) - The Manila Times
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class - GlobeNewswire
Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga
Aug Gainers: Can Cadrenal Therapeutics Inc stock deliver strong Q4 earnings2025 Sector Review & Daily Momentum Trading Reports - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock safe for conservative investorsGap Up & Weekly Market Pulse Updates - Newser
Why Cadrenal Therapeutics Inc. stock attracts global investorsGap Up & Fast Entry Momentum Trade Alerts - Newser
The Technical Signals Behind (CVKD) That Institutions Follow - Stock Traders Daily
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):